Genmab — August 2020
-
-
-
God morgen.
-
-
M.h.t. TV 204 på ESMO, så gjorde han en del ud af dette på Q&A I går, bl.a.: "We very much look forward to discussing these results with the FDA and the potential for the first BLA submission for one of our proprietary therapeutic candidates, which would be an important milestone in our company’s history.."
-
Genmab News - Phase 2 innovaTV 204 study results accepted as a late-breaking abstract at the ESMO Virtual Congress, 2020. Oral presentation is at 17:04 CEST on Sep 21, 2020.
http://ow.ly/gdxj50Ba5F7 -
Finally an update on Epcoritamab in clinicaltrials https://www.clinicaltrials.gov/ct2/history/NCT03625037?A=9&B=10&C=merged#StudyPageTop - large change in Anticipated Enrollment: (from 110 to 386) and participating locations
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind